technology

press releases

Date Title and Summary Additional Formats
Toggle Summary Alder Continues to Expand Leadership Team to Support the Advancement of ALD403 for Migraine Prevention View HTML
Toggle Summary BOTHELL, Wash., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of View HTML
Toggle Summary BOTHELL, Wash., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the View HTML
Toggle Summary Addition to Leadership Team Expands Commercialization Focus and Supports Continued Successful Advancement of ALD403 for Migraine Prevention View HTML
Toggle Summary BOTHELL, Wash., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of View HTML
Toggle Summary Positive 24-Week Clinical Data for ALD403 in Chronic Migraine Continues to Demonstrate a Best-In-Class Profile as Company Advances Toward a BLA Submission Advances Second Program Directed at Migraine Prevention, ALD1910, into IND-Enabling Studies BOTHELL, Wash., July 26, 2016 (GLOBE NEWSWIRE) -- View HTML
Toggle Summary Data to Help Finalize Dose Selection and Design of PROMISE 2, Second Planned Pivotal Study to Start Later this Year View HTML
Toggle Summary BOTHELL, Wash., July 19, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its second quarter 2016 financial and operating results after the close of View HTML
Toggle Summary Alder Continues to Strengthen Leadership Team to Support the Advancement of ALD403 for Migraine Prevention View HTML
Toggle Summary BOTHELL, Wash., June 09, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of View HTML